The Food and Drug Administration (FDA) proposed a new, tougher approach to conflicts of interest among advisors to the agency in March.
The FDA advisory committees, made up of experts on a particular topic, provide recommendations on actions the agency should take on drugs, medical devices, and other FDA-regulated products. The agency typically follows the advice of these panels. Previously, the agency had been criticized for allowing some members of the advisory panels to vote on recommendations that would benefit them financially, and for not having a consistent process for evaluating such conflicts.
Kuehn BM. FDA Advisor Conflicts. JAMA. 2007;297(16):1764. doi:10.1001/jama.297.16.1764-a